From being a Small investment Business to growing into a Company yelling the revenue and Net Worth of about 2500 Crore, Emcure Pharmaceuticals have come a long way and has built its name among the Top Pharmaceutical Companies in India and all across the World.
Emcure Pharmaceutical is a Multinational Company dealing with Pharma Products like Medicines and its Equipment. In This Article we have provided detailed Information On Emcure and its Ventures, Net Worth, Valuation and more.
Emcure Pharmaceutical History
Emcure Pharmaceutical Company was Founded by the renowned Businessman named Satish Mehta. In 1984 after graduating from IIM-A, he started the company with a small loan of ₹3 lakh from the Bank. In the 1990s, the company transitioned from being at the Position of Contract Manufacturer to a Producer of Generic Drugs. In 2006, the company signed license agreements with Bristol- Myers Squibb for Atazanavir and Gilead Sciences for Tenofovir as part of their Global Access Programs.
The Story of Emcure Pharmaceuticals
- In 2012, Roche, a Pharmaceutical company made a deal with Emcure for fabricating its anticancer drugs named Herceptin and Mabthera in India. Under this programme the cancer drugs shall be made accessible to the growing world at an affordable and cheap rate.
- In 2013, Emcurecreated a Health foods venture in collaboration with cricketer MS Dhoni who was also made as the Brand Ambassador of Emcure.
- In 2014, Blackstone sold its 13% stake in Emcure to Bain Capital.
- In 2021, Emcure dissolved its US-based business, including subordinate Heritage Pharmaceuticals, into a new brand called Avet Lifesciences.
- In 2024, Emcure launched its Initial Public Offering and listed on NSE and BSE.
Emcure Pharmaceuticals Owner & CEO
Satish Mehta is the Founder, Chief Executive Officer and Managing Director at the Emcure Pharmaceutical Company. Satish has been an Exceptional and Extraordinary, first-generation entrepreneur and inspiring figure who established the Medicine Agency, Emcure in 1981 with the objective to provide High quality, Budget Friendly and easily accessible healthcare products to Patients to live a Healthy and Safe Life. Under his leadership, Emcure has become a well-known brand in the global pharma market with its presence in more than 70 countries through its subsidiaries in the UK, Canada, Singapore, Brazil and other countries.
Emcure Highlights
Satish Mehta is the prominent entrepreneur for growth and evolution plans of the company. Under his Guidance, Emcure has emerged as one of the top Pharma Companies in India, engaged in manufacturing, developing and marketing a broad range of pharmaceutical products globally. The company has top level framework, expertise and resources approved by foreign drug regulatory authorities of various countries like Europe, Russia, USA, Australia and Brazil.
Through Mehta’s active efforts and initiatives, Emcure has also facilitated Women empowerment for women employees under the PRERNA and NEEM schemes. He has also mentored Emcure’s exceptional CSR initiatives to impact society in varied ways and raise awareness about environmental consciousness.
Emcure Pharmaceuticals Board of Members
The Emcure Pharmaceutical company is vested with a good leadership, consisting of High Profile entrepreneurs who are expert in their specific Fields. Under their Leadership, the company has undergone massive Growth and is yielding high Profits.
| Members | Portfolio |
|---|---|
| Mr.Berjis Minoo Desai | Chairman & Non-Exe.Director |
| Mr.Vijay Keshav Gokhale | Independent Director |
| Mr.Shailesh Kripalu Ayyangar | Independent Director |
| Ms.Vidya Rajiv Yeravdekar | Independent Director |
| Mr.Palamadai Sundararajan Jayakumar | Independent Director |
| Mr.Satish Ramanlal Mehta | Managing Director & CEO |
| Mr.Samonnoi Banerjee | Non Exe. & Nominee Director |
| Mr.Sunil Rajanikant Mehta | Whole Time Director |
| Ms.Namita Vikas Thapar | Whole Time Director |
| Mr.Samit Satish Mehta | Whole Time Director |
| Mr.Mukund Keshao Gurjar | Whole Time Director |
| Mr.Tajuddin Sabir Shaikh | Chief Financial Officer |
| Mr.Chetan Rajendra Sharma | Co. Secretary & Compl. Officer |
Operations Of Emcure Pharmaceuticals
Indian plants
This is the list of manufacturing facilities based in India:
- Solid Dosage facility at Hinjewadi – In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjewadi, Pune. The plant manufactures solid oral formulations for the international regulated markets, but currently under FDA Warning Letter.
- Small volume parenteral facility at Hinjewadi – US FDA, UK MHRA approved. Has Lyophilization and PFS capability, but currently under FDA Warning Letter.
- Oncology injectable facility at Hinjewadi, but currently under FDA Warning Letter.
- Solid Orals facilities at Jammu and Bhosari.API facility at Kurkumbh- US FDA approved
- Biotech facility at Hinjewadi
- R&D Center at Gandhinagar and and plant at Sanand, Ahmedabad – Sanand facility is US FDA approved
US plant
USA – The company has a manufacturing facility and R&D center in East Brunswick, New Jersey, USA.
Emcure Pharmaceuticals IPO GMP
The grey market premium (GMP) for Emcure Pharmaceuticals Limited’s IPO was Rs 295 on July 3, 2024. This was at the upper end of the price band of Rs 960–1,008, which would have resulted in a listing gain of around 29%.
Here are some other details about the Emcure Pharmaceuticals IPO:
- The IPO opened on July 3, 2024 and closed on July 5, 2024.
- The shares were listed on July 10, 2024.
- The issue size was Rs 1,952.03 Cr.
- The IPO was subscribed 67.85 times as of July 5, 2024.
- The minimum investment for retail investors was 14 shares, and the maximum was 196 shares.
- The promoters of the company are Satish Mehta and Sunil Mehta.
GMP is an indicator of how a company’s shares are performing in the unlisted market, but it can change quickly.
Emcure Pharmaceuticals IPO Allotment Status
Here are some details about the Emcure Pharmaceuticals IPO allotment status:
- The basis of allotment was finalized on July 8, 2024
- The allotted shares were credited to demat accounts by July 9, 2024
- The stock was listed on the NSE and BSE on July 10, 2024
The IPO allotment status can be checked on the registrar’s website and the exchange website.
Here are some other details about the Emcure Pharmaceuticals IPO:
- The issue opened for subscription on July 3, 2024 and closed on July 5, 2024
- The total IPO size was ₹1,952.03 cr
- The price band was set at ₹960 to ₹1008
- The lot size was 14 shares
Emcure Pharmaceuticals Share
Here are some of the shareholders of Emcure Pharmaceuticals:
- Promoter group: Holds 78.08% of the shares
- FII: Holds 2.91% of the shares
- DII: Holds 3.96% of the shares
- Retail: Holds 15.05% of the shares
- Samit S Mehta: Holds 7.16% of the shares as of September 2024
- Bhavana Satish Mehta: Holds 4.72% of the shares as of September 2024
- Namita Vikas Thapar: Holds 2.68% of the shares as of September 2024
Emcure Pharmaceuticals Investors
Some of the investors in Emcure Pharmaceuticals include:
- ICICI Pru Healthcare Fund
- Abu Dhabi Investment – Monsoon
- Goldman Sachs India Equity Portfolio
- Nomura India Investment Fund
- HDFC Life Insurance Company
- ICICI Prudential Life Insurance Company
- SBI Life Insurance Company
- Amundi Funds
- Neuberger Berman Emerging Markets Equity Fund
- The Prudential Assurance Company
Emcure Pharmaceuticals Valuation
As of January 8, 2025, Emcure Pharmaceuticals Ltd has a market capitalization of ₹27,469 Cr. Here are some other key metrics for the company:
- Share price: ₹1,450.05 on BSE and ₹1,420.65 on NSE
- P/B ratio: 6.67 times, which is a 46% premium to its peers’ median range
- P/E ratio: 55.14 times, which is a 23% discount to its peers’ median range
- Total asset value: ₹7,709 Cr as of March 31, 2024
Emcure Pharmaceuticals Net Worth
As of September 30, 2024, Emcure Pharmaceuticals’ total assets were Rs 12,968.19 million, and total net profit after tax was Rs 121.19 million.
Here are some other financial highlights for Emcure Pharmaceuticals in 2024:
- Total assets and liabilities: Total assets and liabilities for FY24 were Rs 77 billion, up from Rs 66 billion in FY23.
- Current liabilities: Current liabilities for FY24 were Rs 32 billion, up from Rs 30 billion in FY23.
- Long-term debt: Long-term debt for FY24 was Rs 8 billion, up from Rs 7 billion in FY23.
- Current assets: Current assets for FY24 were Rs 43 billion, up 11% from FY23.
- Fixed assets: Fixed assets for FY24 were Rs 34 billion, up 26% from FY23.
- Net sales: Consolidated net sales for September 2024 were Rs 2,001.98 crore, up 20.38% year-on-year.
- Standalone net sales: Standalone net sales for September 2024 were Rs 1,104.63 crore, up 24.4% year-on-year.
